CLAIMS

What is claimed is:

1. A compound of formula I,

A-X G L O R3 R2 R7

in which

10

15

20

5

A is (C_1-C_8) alkyl, (C_0-C_8) alkylenearyl; a 3- to 12-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O and S and the 3- to 12-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, OCF₃, CN, (C_1-C_6) alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C₁-C₆)alkyl, S-(C₁-C₆)alkyl, and NHCO(C₁-C₆)alkyl;

X is a bond, C(R8)(R9), C(OR10)(R11), O, N(R12), S, SO, SO₂, or CO;

R8, R9, R10, R11, R12 are independently of one another H, or (C₁-C₆)alkyl;

D is N, or C(R41);

E is N, or C(R42);

25

G is N, or C(R43);

L is N, or C(R44);

R1, R2, R3, R41, R42, R43, R44 are independently of one another H, F, Cl, Br, J, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)alkyl, (C₁-C₄)alkoxyalkyl, S-(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₃-C₈)cycloalkyl, O-(C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkenyl, (C₂-C₆)alkynyl, (C₀-C₈)alkylenearyl, -O-(C₀-C₈)alkylenearyl, S-aryl, N(R13)(R14), SO₂-CH₃, COOH, COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), CO(R21), or a 5- to 7-membered heterocycle having 1-4 heteroatoms;

R13, R14 are independently of one another H, (C_1-C_6) alkyl, or R13 and R14 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R15, R16 are independently of one another H, (C₁-C₆)alkyl, or R15 and R16 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R17, R19 are independently of one another H, or (C₁-C₆)alkyl;

R18, R20, R21 are independently of one another (C₁-C₆)alkyl, or aryl;

B is N(R24), or O;

25

20

10

R24 is H, or (C₁-C₆)alkyl;

R5 is H, or (C_1-C_6) alkyl;

W is N, or C(R25);

R25 is H, (C_1-C_6) alkyl, aryl, or a bond to Y;

T is N, or C(R26);

R26 is H, (C₁-C₆)alkyl, aryl, (C₀-C₈)alkylenearyl, or a bond to Y;

5 U is O, S, N(R27), -C(R30)=N-, or -N=C(R31)-;

R27, R30, R31 are independently of one another H, (C_1-C_6) alkyl, or a bond to Y;

10 Y is (C₁-C₈)alkylene, in which one or more carbons may be replaced by O, S, SO, SO₂, C(R32)(R33), CO, C(R34)(OR35) or N(R36);

R32, R33, R34, R35, R36 are independently of one another H, (C₁-C₆)alkyl, or aryl;

15

20

25

R6, R7 are independently of one another H, (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, or R6 and Y or R6 and R7 together with the nitrogen atom to which they are bonded form a 3- to 8-membered ring in which one or more carbons may be replaced by O, N or S and the 3- to 8-membered ring may carry further substituents such as (C_1-C_6) alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, $O-(C_1-C_6)$ alkyl or $NHCO(C_1-C_6)$ alkyl;

R37, R38, R39, R40 are independently of one another H, or (C₁-C₆)alkyl; and the physiologically acceptable salts thereof.

2. A compound of formula I as claimed in claim 1, wherein

A is (C₂-C₇)alkyl, (C₀-C₃)alkylenearyl; a 4- to 10-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O and S, and the 4- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), O-(C₁-C₆)alkyl, and NHCO(C₁-C₆)alkyl;

X is a bond, C(R8)(R9), O, N(R12), S, or SO₂;

R8, R9, R12 are independently of one another H, or (C₁-C₆)alkyl;

5

20

25

30

- D is N, or C(R41);
- E is N, or C(R42);
- 10 G is N, or C(R43);
 - L is N, or C(R44);

where the total number of the nitrogen atoms defined by D, E, G and L is 0, 1 or 2;

R1, R2, R3, R41, R42, R43, R44 are independently of one another H, F, Cl, Br, CF₃, NO₂, O-(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, O-(C₃-C₈)cycloalkyl, (C₂-C₆)alkynyl, (C₀-C₈)alkylenearyl, -O-(C₀-C₃)alkylenearyl, S-aryl, N(R13)(R14), SO₂-CH₃, COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), or CO(R21);

R13, R14 are independently of one another H, (C_1-C_6) alkyl, or R13 and R14 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R15, R16 are independently of one another H, (C₁-C₆)alkyl, or R15 and R16 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R17, R19 are independently of one another H, or (C_1-C_6) alkyl;

R18, R20, R21 are independently of one another (C₁-C₆)alkyl, or aryl;

B is N(R24), or O;

5

R24 is H, or (C_1-C_6) alkyl;

R5 is H, or (C_1-C_6) alkyl;

W is N, or C(R25);

R25 is H, (C_1-C_6) alkyl, or aryl;

T is C(R26);

15

20

25

30

10

R26 is H, (C₁-C₆)alkyl, aryl, or a bond to Y;

U is O, S, N(R27), or -N=C(R31)-;

R27, R31 are independently of one another H, (C₁-C₆)alkyl, or a bond to Y;

Y is (C_1-C_4) alkylene, in which a carbon may be replaced by SO_2 , C(R32)(R33), CO or N(R36);

R32, R33, R36 are independently of one another H, (C₁-C₆)alkyl, or aryl;

R6, R7 are independently of one another H, (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, or R6 and Y or R6 and R7 together with the nitrogen atom to which they are bonded form a 4- to 7-membered ring in which one or more carbons may be replaced by O, N or S and the 4- to 7-membered ring may carry further substituents selected from the group consisting of (C_1-C_6) alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH and $NHCO(C_1-C_6)$ alkyl;

R37, R38, R39, R40 are independently of one another H, or (C₁-C₆)alkyl; and the physiologically acceptable salts thereof.

- 3. A compound of formula I as claimed in either of claims 1 and 2, wherein
- A is (C_3-C_7) alkyl, (C_0-C_2) alkylenearyl; a 5- to 10-membered mono- or bicyclic ring which may contain 0, 1 or 2 heteroatoms selected from the group consisting of N, O and S, and the 5- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, (C_1-C_6) alkyl, aryl, O- (C_1-C_6) alkyl and NHCO (C_1-C_6) alkyl;
 - X is a bond, C(R8)(R9), O, or N(R12);

15

5

10

R8, R9, R12 are independently of one another H, or (C₁-C₆)alkyl;

- D is N, or C(R41);
- E is N, or C(R42);
 - G is N, or C(R43);
 - L is N, or C(R44);

25

where the total number of the nitrogen atoms defined by D, E, G and L is 0 or 1;

R1, R2, R3, R41, R42, R43, R44 are independently of one another H, F, Cl, CF₃, NO₂, O-(C₁-C₆)alkyl, (C₁-C₆)alkyl, O-(C₃-C₈)cycloalkyl, (C₀-C₂)alkylenearyl, - O-(C₀-C₃)alkylenearyl, N(R13)(R14), COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), or CO(R21);

```
R13, R14 are independently of one another H, or (C_1-C_6)alkyl,
```

5 R17, R19 are independently of one another H, or (C₁-C₆)alkyl;

R18, R20, R21 are independently of one another (C₁-C₆)alkyl, or aryl;

B is N(R24);

10

R24 is H, or (C_1-C_6) alkyl;

R5 is H, or (C_1-C_6) alkyl;

15 W is N, or C(R25);

R25 is H, or (C_1-C_6) alkyl;

T is C(R26);

20

R26 is H, (C₁-C₆)alkyl, or a bond to Y;

U is O, S, or N(R27);

25 R27 is H, (C₁-C₆)alkyl, or a bond to Y;

Y is (C_1-C_3) alkylene, in which a carbon may be replaced by SO_2 , C(R32)(R33) or CO;

R32, R33 are independently of one another H, (C₁-C₆)alkyl, or aryl;

R6, R7 are independently of one another H, (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, or R6 and Y or R6 and R7 together with the nitrogen atom to which

they are bonded form a 5- or 6-membered ring in which one or more carbons may be replaced by O or N and the 5- or 6-membered ring may carry further substituents selected from the group consisting of (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH and NHCO(C₁-C₆)alkyl;

5

R37, R38, R39, R40 are independently of one another H, or (C₁-C₆)alkyl; and the physiologically acceptable salts thereof.

10

15

- 4. A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1 and a physiologically acceptable carrier.
- 5. A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1, one or more anorectic active substances and a physiologically acceptable carrier.
- 6. A method for the prophylaxis or treatment of obesity comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

20

7. A method for the prophylaxis or treatment of type II diabetes comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

25

8. The method of claim 6, further comprising administering an effective amount of an anorective active substance.

•

9. The method of claim 7, further comprising administering an effective amount of an anorective active substance.

30

10. A method for preparing a pharmaceutical comprising one or more of the compounds as claimed claim 1, which comprises mixing the active substance

with a pharmaceutically suitable carrier and bringing said mixture into a form suitable for administration.

- 11. A method for the prophylaxis or treatment of arterioscerosis or high blood pressure comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.
- 12. A method for normalizing lipid metabolism comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.
 - 13. A method for the prophylaxis or treatment of paresthesia, depression, anxiety, anxiety neuroses, or schizophrenia comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

15

20

- 14. A method for the prophylaxis or treatment of disorders associated with the circadian rhythm comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.
- 15. A method for the treatment of drug abuse comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.